ALDX Aldeyra: Accounting Value per Share

Graphic logo of Aldeyra Therapeutics, Inc. (ALDX)

This daily price chart for Aldeyra Therapeutics (ALDX) with the 0.64 indicator reflects the price action of an asset whose returns are decoupled from economic cycles due to stable demand for ophthalmological therapy. Aldeyra Therapeutics is implementing AI and automation to accelerate formula selection, thereby reducing manual labor. A narrow focus on treating immune ocular pathologies is offset by the market launch of key drugs.

Aldeyra (ALDX): Share Book Value from 07/04/2022 to 10/28/2026

Aldeyra Therapeutics Inc. - analytical breakdowns and key metrics (ALDX)

- price and consensus price forecast:
Stock Price Aldeyra|ALDX - Broker Consensus Forecast
- market capitalization data:
Market Valuation Aldeyra Therapeutics, Inc.|ALDX - Business Value
- book capitalization data:
Net Assets per Single Share Aldeyra Therapeutics|ALDX - Net Asset Value|Market Capitalization to Book Value Ratio aldeyra.com|ALDX - Aggregate Asset Value
- debt and liquidity data:
Total Debt to Capital Aldeyra Therapeutics|ALDX - Long-Term Debt to Capital|Short-Term Debt to Equity Aldeyra|ALDX - Aggregate Debt Obligations|Debt to Book Capitalization Ratio Aldeyra Therapeutics, Inc.
Fundamental company valuation:aldeyra.com - ALDX
Manufactured products of Aldeyra

Steady demand for ocular pathology therapies strengthens the market position of Aldeyra Therapeutics (ALDX), which is directly reflected in the company's equity structure. The bps metric trend demonstrates the ratio of net assets to the number of shares, allowing investors to assess the real value of assets net of liabilities and determine the business's fundamental margin of safety, stripped of market volatility.

Competitors of Aldeyra Therapeutics (ALDX)

Alcon Vision (ALC) - Book Value per Share|Bausch Health (BLCO) - Equity per Share|Accounting Value per Share Glaukos Corporation|APLS (apellis.com) - Equity per Share|Net Assets per Single Share belitebio.com BLTE|Share Book Value Ocular Therapeutix Inc|Harrow Health (HROW) - Book Value per Share|Accounting Value of a Share Viridian Corp (VRDN)|Book Value per Share LENZ (LENZ Therapeutics, Inc.)|Oculis Pharma - Book Value per Share|Net Assets per Single Share EyePoint Pharmaceuticals, Inc. (EYPT)|KOD: Accounting Value of a Share|KALA (kalarx.com) - Net Assets per Single Share|Opus Genetics (IRD) - Accounting Value per Share|OKYO (OKYO Pharma Ltd) - Book Value per Share|Book Value per Share Adverum (ADVM)|Outlook Therapeutics, Inc. (OTLK) - Accounting Value per Share|Accounting Value of a Share Clearside Biomedical Inc (CLSD)|NBY: Book Value per Share|KPRX - Net Asset Value per Share|ALIM (Alimera) - Accounting Value per Share|EYEN - Net Asset Value per Share|Book Value per Share GHSI|OCUP (Ocuphire Pharma Inc) - Net Asset Value per Share|OPT: Net Assets per Single Share